On the contrary, individuals with JMML and homozygous CBL mutations who undergo HSCT seem not to develop vasculitis, suggesting that a normal immune/hematopoietic system could be pivotal in preventing these manifestations [6]. The gene discussed is CBL; the disease is vasculitis.